Acumen Pharmaceuticals (ABOS) Cash from Financing Activities (2021 - 2026)

Acumen Pharmaceuticals (ABOS) has 6 years of Cash from Financing Activities data on file, last reported at $35.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 99383.33% year-over-year to $35.7 million; the trailing twelve-month figure through Mar 2026 stood at $35.7 million (up 16725.12% YoY), and the FY2025 full-year result was -$34000.0, down 100.49% from the prior year.
• Cash from Financing Activities climbed to $35.7 million in Q1 2026, from $2000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $122.8 million in Q3 2023 to a low of -$263000.0 in Q3 2022.
• A 5-year average of $16.5 million and a median of -$3500.0 in 2024 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities slumped 100.51% in 2025 and soared 99383.33% in 2026, its largest moves.
• Tracing ABOS's Cash from Financing Activities over 5 years: stood at $4.2 million in 2022, then soared by 596.32% to $29.1 million in 2023, then sank by 100.03% to -$9000.0 in 2024, then soared by 122.22% to $2000.0 in 2025, then surged by 1787000.0% to $35.7 million in 2026.
• Business Quant data shows ABOS's Cash from Financing Activities at $35.7 million in Q1 2026, $2000.0 in Q4 2025, and -$36000.0 in Q1 2025.